12-4-1　ⓔ文献

  1. Fattovich G, Bortolotti F, et al: Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol, 2008; 48: 335–352.

  2. Sugauchi F, Orito E, et al: Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. Hepatol Res, 2006; 36: 107–114.

  3. Yuen MF, Chen DS, et al: Hepatitis B virus infection. Nat Rev Dis Primers, 2018; 4: 18035.

  4. Miyakawa Y, Mizokami M: Classifying hepatitis B virus genotypes. Intervirology, 2003; 46: 329–338.

  5. Matsuura K, Tanaka Y, et al: Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol, 2009; 47: 1476–1483.

  6. Buster EH, Hansen BE, et al: Factors that predict response of patients with hepatitis B e antigen–positive chronic hepatitis B to peginterferon–alfa. Gastroenterology, 2009; 137: 2002–2009.

  7. Janssen HL, van Zonneveld M, et al: Pegylated interferon alfa–2b alone or in combination with lamivudine for HBeAg–positive chronic hepatitis B: a randomised trial. Lancet, 2005; 365: 123–129.

  8. Ozasa A, Tanaka Y, et al: Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology, 2006; 44: 326–334.

  9. Sugauchi F, Orito E, et al: Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology, 2003; 124: 925–932.

  10. Fisicaro P, Valdatta C, et al: Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut, 2009; 58: 974–982.

  11. Bility MT, Cheng L, et al: Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human–specific liver fibrosis and M2–like macrophages. PLoS Pathog, 2014; 10: e1004032.

  12. Lv Y, Cui M, et al: Expression and significance of peripheral myeloid–derived suppressor cells in chronic hepatitis B patients. Clin Res Hepatol Gastroenterol, 2018; 42: 462–469.

  13. van der Molen RG, Sprengers D, et al: Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. Hepatology, 2006; 44: 907–914.

  14. Duan XZ, Wang M, et al: Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans. J Clin Immunol, 2004; 24: 637–646.

  15. Guo J, Gao Y, et al: Frequencies of dendritic cells and Toll–like receptor 3 in neonates born to HBsAg–positive mothers with different HBV serological profiles. Epidemiol Infect, 2015; 143: 62–70.

  16. Stelma F, de Niet A, et al: Natural killer cell characteristics in patients with chronic hepatitis B virus (HBV) infection are associated with HBV surface antigen clearance after combination treatment with pegylated interferon alfa–2a and adefovir. J Infect Dis, 2015; 212: 1042–1051.

  17. Ye B, Liu X, et al: T–cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis, 2015; 6: e1694.

  18. TrehanPati N, Kotillil S, et al: Circulating Tregs correlate with viral load reduction in chronic HBV–treated patients with tenofovir disoproxil fumarate. J Clin Immunol, 2011; 31: 509–520.

  19. Stoop JN, van der Molen RG, et al: Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology, 2005; 41: 771–778.

  20. Stoop JN, van der Molen RG, et al: Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology, 2007; 361: 141–148.

21) Xu D, Fu J, et al: Circulating and liver resident CD4＋CD25＋ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol, 2006; 177: 739–747.

  1. Ringelhan M, Pfister D, et al: The immunology of hepatocellular carcinoma. Nat Immunol, 2018; 19: 222–232.

  2. Zhao LH, Liu X, et al: Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma. Nat Commun, 2016; 7: 12992.

  3. Ali A, Abdel–Hafiz H, et al: Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma. World J Gastroenterol, 2014; 20: 10238–10248.

  4. Li TN, Wu YJ, et al: Intrahepatic hepatitis B virus large surface antigen induces hepatocyte hyperploidy via failure of cytokinesis. J Pathol, 2018; 245: 502–513.

  5. Terrault NA, Bzowej NH, et al: AASLD guidelines for treatment of chronic hepatitis B. Hepatology, 2016; 63: 261–283.

  6. Hung TH, Liang CM, et al: Association between complicated liver cirrhosis and the risk of hepatocellular carcinoma in Taiwan. PLoS One, 2017; 12: e0181858.

  7. Fattovich G, Stroffolini T, et al: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology, 2004; 127: S35–S50.

  8. Tseng TC, Liu CJ, et al: High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology, 2012; 142: 1140–1149.

  9. 日本肝臓学会肝炎診療ガイドライン作成委員会：B型肝炎治療ガイドライン 第3.1版，2019.

  10. Fanning GC, Zoulim F, et al: Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019; 18: 827–844.

  11. Ono A, Suzuki F, et al: Long–term continuous entecavir therapy in nucleos (t) ide–naive chronic hepatitis B patients. J Hepatol, 2012; 57: 508–514.

  12. Tenney DJ, Rose RE, et al: Long–term monitoring shows hepatitis B virus resistance to entecavir in nucleoside–naive patients is rare through 5 years of therapy. Hepatology, 2009; 49: 1503–1514.

  13. Suk-Fong Lok A: Hepatitis B treatment: what we know now and what remains to be researched. Hepatol Commun, 2019; 3: 8–19.

  14. Doi A, Sakamori R, et al: Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all–oral direct-acting antivirals: analysis of a Japanese prospective cohort. Hepatol Res, 2017; 47: 1438–1444.

  15. Li J, Chang MS, et al: Management of chronic hepatitis B in pregnancy. J Clin Gastroenterol, 2017; 51: 789–795.

  16. Averhoff F, Mahoney F, et al: Immunogenicity of hepatitis B vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med, 1998; 15: 1–8.

  17. Doi H, Yoshio S, et al: Immune determinants in the acquisition and maintenance of antibody to hepatitis B surface antigen in adults after first-time hepatitis B vaccination. Hepatol Commun, 2019; 3: 812–824.

  18. Stramer SL, Wend U, et al: Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med, 2011; 364: 236–247.